These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 30762302)

  • 1. Exposure-Response-Based Product Profile-Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer.
    Zhu R; Poland B; Wada R; Liu Q; Musib L; Maslyar D; Cho E; Yu W; Ma H; Jin JY; Budha N
    CPT Pharmacometrics Syst Pharmacol; 2019 Apr; 8(4):240-248. PubMed ID: 30762302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of exposure-response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study.
    Kotani N; Wilkins JJ; Wade JR; Dang S; Sutaria DS; Yoshida K; Sundrani S; Ding H; Garcia J; Hinton H; Sane R; Chanu P
    Cancer Chemother Pharmacol; 2022 Dec; 90(6):511-521. PubMed ID: 36305957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
    Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib.
    Malhi V; Budha N; Sane R; Huang J; Liederer B; Meng R; Patel P; Deng Y; Cervantes A; Tabernero J; Musib L
    Cancer Chemother Pharmacol; 2021 Dec; 88(6):921-930. PubMed ID: 34471960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships.
    Venkatakrishnan K; Zhou X; Ecsedy J; Mould DR; Liu H; Danaee H; Fingert H; Kleinfield R; Milton A
    J Clin Pharmacol; 2015 Mar; 55(3):336-47. PubMed ID: 25302940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss.
    de Bono JS; De Giorgi U; Rodrigues DN; Massard C; Bracarda S; Font A; Arranz Arija JA; Shih KC; Radavoi GD; Xu N; Chan WY; Ma H; Gendreau S; Riisnaes R; Patel PH; Maslyar DJ; Jinga V
    Clin Cancer Res; 2019 Feb; 25(3):928-936. PubMed ID: 30037818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer.
    Oliveira M; Saura C; Nuciforo P; Calvo I; Andersen J; Passos-Coelho JL; Gil Gil M; Bermejo B; Patt DA; Ciruelos E; de la Peña L; Xu N; Wongchenko M; Shi Z; Singel SM; Isakoff SJ
    Ann Oncol; 2019 Aug; 30(8):1289-1297. PubMed ID: 31147675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients.
    Yoshida K; Wilkins J; Winkler J; Wade JR; Kotani N; Wang N; Sane R; Chanu P
    J Clin Pharmacol; 2021 Dec; 61(12):1579-1591. PubMed ID: 34273118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.
    Saura C; Roda D; Roselló S; Oliveira M; Macarulla T; Pérez-Fidalgo JA; Morales-Barrera R; Sanchis-García JM; Musib L; Budha N; Zhu J; Nannini M; Chan WY; Sanabria Bohórquez SM; Meng RD; Lin K; Yan Y; Patel P; Baselga J; Tabernero J; Cervantes A
    Cancer Discov; 2017 Jan; 7(1):102-113. PubMed ID: 27872130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gleevec: zeroing in on cancer.
    Capriotti T
    Medsurg Nurs; 2002 Dec; 11(6):301-4. PubMed ID: 12520979
    [No Abstract]   [Full Text] [Related]  

  • 11. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
    Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
    J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.
    George DJ; Halabi S; Healy P; Barak I; Winters C; Anand M; Wilder R; Klein M; Martinez E; Nixon AB; Harrison MR; Szmulewitz R; Armstrong AJ
    Prostate; 2019 Nov; 79(15):1752-1761. PubMed ID: 31497882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib treatment of metastatic GIST: don't stop (believing).
    Heinrich MC
    Lancet Oncol; 2010 Oct; 11(10):910-1. PubMed ID: 20864404
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer.
    Miller K; Moul JW; Gleave M; Fizazi K; Nelson JB; Morris T; Nathan FE; McIntosh S; Pemberton K; Higano CS
    Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):187-92. PubMed ID: 23381694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
    Fizazi K; Massard C; Bono P; Jones R; Kataja V; James N; Garcia JA; Protheroe A; Tammela TL; Elliott T; Mattila L; Aspegren J; Vuorela A; Langmuir P; Mustonen M;
    Lancet Oncol; 2014 Aug; 15(9):975-85. PubMed ID: 24974051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
    Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
    Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme.
    Maines F; Caffo O; De Giorgi U; Fratino L; Lo Re G; Zagonel V; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Ermacora P; Messina C; Giordano M; Alesini D; Basso U; Fraccon AP; Vicario G; Conteduca V; Galligioni E
    Clin Genitourin Cancer; 2016 Feb; 14(1):48-55. PubMed ID: 26382222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
    Martin GA; Chen AH; Parikh K
    Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-dose, randomized crossover comparisons of different-strength imatinib mesylate formulations in healthy Korean male subjects.
    Kim KA; Park SJ; Kim C; Park JY
    Clin Ther; 2013 Oct; 35(10):1595-602. PubMed ID: 24060561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.